

References

I-9

1. Zimran A, Pastores GM, Tytki-Szymanska A, et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. *Am J Hematol.* 2013;88:172-178.
2. Gonzalez DE, Turkia HB, Lukina EA, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. *Am J Hematol.* 2013;88(3):166-71.
3. Pastores G, Rosenbloom B, Weinreb N, et al. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. *Genet Med.* 2014;(5):359-66.
4. Zimran A, Gonzalez-Rodriguez D, Abrahamov A, et al. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. *Blood Cells Mol Dis.* 2015;54(1):9-16.
5. Vigan M, Stirnemann J, Caillaud C, et al. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model. *Orphanet J Rare Dis.* 2014;9:95.
6. Abbas R, Park G, Damle B, et al. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease. *PLoS One.* 2015;8;10(6).
7. Hughes D, Gonzalez D, Lukina A, et al. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials. *Am J Hematol.* 2015;90(7):584-91.
8. Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, et al. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase. *Blood Cells Mol Dis.* 2016 doi: 10.1016/j.bcmd.2016.10.005.
9. Serratrice C, Carballo S, Serratrice J and Stirnemann J. Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. *Core Evid.* 2016;11:37-47. doi: 10.2147/CE.S93717.
10. vanDussen L, Cox TM, Hendriks EJ, et al. Effects of switching from a reduced imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes. *Haematologica.* 2012;1850-1854.
11. Elstein D, Burrow TA, Charrow J, et al. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease. *Mol Genet Metab.* 2016;1-5.
12. Elstein D, Abrahamov A, Oz A, et al. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease. *Bld Cell Mol Dis.* 2015;415-418.

13. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. Healthcare. 2016. Accessed November 9, 2017.
14. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2017.
15. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
16. MICROMEDEX®SOLUTIONS Compendia. 2017. Imiglucerase.
17. MICROMEDEX®SOLUTIONS Compendia. 2017. Velaglucerase Alfa.
18. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Imiglucerase.
19. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Taliglucerase Alfa.
20. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Velaglucerase Alfa.

